NIKTIMVO J Code: J9038

Drug & Product Overview

HCPCS Descriptor Injection, axatilimab-csfr, 0.1 mg

HCPCS Added Date April 1, 2025

Manufacturer Incyte Corporation

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection

About NIKTIMVO

Niktimvo is a medication aligned to the HCPCS J Code: J9038 for billing, pricing, and reimbursement purposes in the United States. Classified under Oncology, it is administered via the intravenous route and manufactured by Incyte Corporation.

According to CMS Drug Use Information: This medication is used to treat a certain problem that may occur after a stem cell transplant (chronic graft-versus-host disease). Axatilimab belongs to a class of medications known as monoclonal antibodies. It works by blocking some of your immune system's responses which may cause swelling and scarring of certain organs or parts of the body.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Package	Manufacturer	HCPCS Units	WAC	AWP
50881-0023-11	22 MG / 0.44 ML Niktimvo Intravenous Injection 22 MG/0.44ML - 1 VIAL, SINGLE-USE in 1 CARTON (50881-023-11) / .44 mL in 1 VIAL, SINGLE-USE	Incyte Corporation	220	$11,968.00 $54.40 / unit	$14,361.60 $65.28 / unit
50881-0034-12	9 MG / 0.18 ML Niktimvo Intravenous Injection 9 MG/0.18ML - 1 VIAL, SINGLE-USE in 1 CARTON (50881-034-12) / .18 mL in 1 VIAL, SINGLE-USE	Incyte Corporation	90	$4,896.00 $54.40 / unit	$5,875.20 $65.28 / unit
50881-0036-17	9 MG / 0.9 ML Niktimvo Intravenous Injection 9 MG/0.9ML - 1 VIAL, SINGLE-USE in 1 CARTON (50881-036-17) / .9 mL in 1 VIAL, SINGLE-USE	Incyte Corporation	90	$4,896.00 $54.40 / unit	$5,875.20 $65.28 / unit
50881-0047-18	22 MG / 2.2 ML Niktimvo Intravenous Injection 22 MG/2.2ML - 1 VIAL, SINGLE-USE in 1 CARTON (50881-047-18) / 2.2 mL in 1 VIAL, SINGLE-USE	Incyte Corporation	220	$11,968.00 $54.40 / unit	$14,361.60 $65.28 / unit

Effective 8/24/26 (WAC & AWP)

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

NIKTIMVO Pricing & Reimbursement

J9038 Private Payer Reimbursement

$55.49 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

NDC Package

HCPCS Units

Markup / Markdown

%

Common:

Estimates only. Payer reimbursement varies by contract, site of care, and sequestration.

Estimated Reimbursement

NIKTIMVO Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 18.29%

Avg. Days to File 8.4days

Avg. Days to Pay 35.7days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J9038 claims analytics on FocalPoint →

NIKTIMVO CPT Administration Codes

CPT Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

NIKTIMVO Medically Unlikely Edits (MUE)

The most billing units of J9038 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 0.1 mg.

Practitioner Office & Hospital Outpatient

360 units / day

= 36 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

NIKTIMVO Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Chronic graft-versus-host disease (cGVHD)

Drug Class

Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors [MoA]Colony Stimulating Factor-1 Receptor Blocker [EPC]

Frequently Asked Questions

Is there an available NIKTIMVO billing and coding guide?

Billing and coding information for NIKTIMVO can be found through Incyte Corporation. Visit Here →

Are there any available NIKTIMVO patient assistance programs?

NIKTIMVO patient assistance information can be found through Incyte Corporation. Visit Here →

Where can I find NIKTIMVO prescribing information?

NIKTIMVO prescribing information can be found at the link below: Visit Here →

Where can I find NIKTIMVO side effect information?

Information regarding NIKTIMVO's side effects can be found at MedlinePlus

Does billing NIKTIMVO require JZ/JW wastage modifiers?

CMS does not include NIKTIMVO (J9038) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J9038. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.